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Elderly and poor performance status advanced non-small-cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly.
Special approaches are needed for these patient populations. Gefitinib (Iressa) was used in 59 elderly and/or unfit NSCLC pretreated
patients participating in a compassionate use programme showing some activity and good tolerability.
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More than 50% of lung cancer patients are diagnosed over the age
of 65 years and about 30% over the age of 70 years. Elderly patients
tolerate chemotherapy poorly compared to their younger counter-
part because of the progressive reduction of organ function and
comorbidities related to age (Gridelli et al, 2002).
We previously showed, in a randomised phase III trial (ELVIS –
Elderly Lung cancer Vinorelbine Italian Study), that single-agent
vinorelbine improves quality of life and survival as compared to
supportive care alone in advanced NSCLC elderly patients (Elderly
Lung cancer Vinorelbine Italian Study Group, 1999). More
recently, in a large randomised phase III trial (MILES –
Multicenter Italian Lung cancer in the Elderly Study), we did not
find any advantage for combination chemotherapy with gemcita-
bine plus vinorelbine as compared to single-agent vinorelbine or
gemcitabine (Gridelli et al, 2003b). Therefore, single-agent
chemotherapy is considered by many as the standard treatment
for advanced NSCLC elderly patients.
For patients with poor Eastern Cooperative Oncology Group
performance status (ECOG PS 2), there is no treatment widely
accepted as standard, and oncologists have to choose among
several treatment options ranging from best supportive care to
platinum-based combination chemotherapy (Bunn, 2002; Gridelli
et al, 2003a). However, these patients usually experience severe
chemotherapy-induced toxicity. Furthermore, several patients at
diagnosis have major comorbidities contraindicating any che-
motherapy. The possibility to develop and use well-tolerated new
targeted therapies even as first-line treatment in these groups of
patients is of great interest.
The epidermal growth factor receptor (EGFR) autocrine pathway
contributes to a number of processes important to cancer
development and progression, including cell proliferation, apoptosis,
angiogenesis, and metastatic spread (Ciardiello and Tortora, 2001).
Gefitinib (ZD1839) (Iressa) is an orally available EGFR tyrosine
kinase inhibitor. The major clinical development of gefitinib has
been reported for single-agent therapy in recurrent NSCLC. In fact,
recently, two large randomised phase II trials, named IDEAL-1 and
IDEAL-2 (Iressa Dose Evaluation in Advanced Lung cancer),
evaluating the activity of two different doses of gefitinib in
pretreated NSCLC patients, demonstrated that Iressa, at a daily
dose of 250mg, is active and well tolerated (Kris et al, 2002;
Fukuoka et al, 2003). Response rates ranged between 20% for
patients pretreated with one or two chemotherapy lines (IDEAL-1
trial) and 10% for patients pretreated with two or more
chemotherapy lines (IDEAL-2 trial). Although IDEAL-1 and -2
are randomised phase II trials, they confirm gefitinib 250mg daily
as an important novel treatment option for patients with
pretreated advanced NSCLC and gefitinib has been very recently
licensed by Japan, Australia and United States Food and Drug
Administration for use in this NSCLC setting.
Considering its good safety profile, a further prospective of
gefitinib use should be developed in the treatment of special
patient populations, such as PS 2–3 patients, elderly and patients
with major comorbidities contraindicating any chemotherapy.
In the present paper, we report tolerability and activity of
gefitinib in 59 elderly and/or PS 2 or more patients, treated within
a compassionate use programme.
MATERIALS AND METHODS
Patients with the following inclusion criteria and included in the
AstraZeneca’s compassionate use programme were considered for
retrospective analysis: histologically or cytologically confirmed
advanced NSCLC; at least one prior chemotherapy regimen or
radiation therapy for advanced disease or ineligible for che-
motherapy or radiotherapy for any reason, age 470 years with
ECOG PS40 or younger with PSX2; at least one bidimensionally
measurable lesion. Adequate hepatic, renal and bone marrow
function were required. All patients gave written informed consent.
Objective responses were evaluated according to World Health
Organisation (WHO) criteria (Miller et al, 1981). Cranial, thoracic,
abdominal CT scans were performed at baseline and every 2
months. Toxicity was graded according to WHO criteria before
each cycle of therapy (Miller et al, 1981).
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lAccording to the compassionate use programme, gefitinib was
administered orally at a dose of 500mg (divided in two doses) on
day 1 and then as a once daily dose of 250mg until disease
progression, the appearance of unacceptable toxicity, or patient’s
withdrawal of consent. Patients were instructed to take the daily
dose preferably in the morning. During the treatment period, no
other medication with activity against NSCLC was allowed.
RESULTS
From September 2001 to April 2003, 59 patients, 18 elderly (age
470 years) and 41 unfit (PS42), treated in our Institution were
analysed and evaluable for response and toxicity. The character-
istics of patients are reported in Table 1. Median age was 62 years
(range 38–80 years); PS was one in four patients, two in 40 and
three in 15; male/female in 43/16 cases; stage IIIB and IV in seven
and 52 patients, respectively. The histologic types were squamous
cell carcinoma in 27, adenocarcinoma in 27, bronchioloalveolar in
one and undefined NSCLC in four patients. The gefitinib was
administered in two patients as first-line, in 23 as second-line and
in 34 as third-line treatment or more. In the previous treatments,
25 (42.3%) patients received a platinum-based regimen and 15
(25.4%) both a platinum- and a docetaxel-based regimens.
Overall, three (5%) patients remained on treatment for 43
months and six (10.1%) of them for 46 months. The most
common reported adverse events were grade 1 and 2 skin changes
in four (6.7%) and one (1.6%) patients, respectively. Grade 1
diarrhoea in five (8.4%) patients. Grade 2 hypertransaminasaemia
in one (1.6%) patient. There were two partial responses (PR)
(3.4%, 95% exact binomial confidence limit: 0.4–11.7) and seven
(11.8%) stable disease with an overall control of disease in 15.2%
of cases. All the responses were reported in adenocarcinoma (two
females) in which the EGFR expression was not available because
the diagnosis was performed with a CT-guided fine-needle ago
biopsy. Median progression-free survival was 7.2 weeks (range
2.1–57.1þ). Median overall survival was 18.8 weeks (range 4.5–
68.7þ). At the cutoff date of July 30, 2003, 12 (20.3%) patients
were still alive and four (6.7%) of them on gefitinib treatment.
Results are summarised in Table 2.
DISCUSSION
Elderly and unfit patients with advanced NSCLC often are
unsuitable for standard chemotherapy, because of their sensitive-
ness to treatment toxicity. In recent years, the rapidly expanding
knowledge of cancer molecular pathogenesis has provided new
targets for anticancer treatment. Some new biologic agents, such as
gefitinib, have characteristics allowing their evaluation in this
special patient population: low toxicity profile and oral formula-
tion, both with potential advantages for patients.
In the present paper, we report an excellent safety profile for
gefitinib in a series of 59 elderly and/or poor PS patients. No grade
3 or 4 adverse events have been registered. This toxicity profile is
clearly better as compared to that reported with second- and third-
line chemotherapy, even in younger and fit patients (Fossella et al,
2000; Shepherd et al, 2000). It is to underline that nearly all
patients included in this analysis were heavily pretreated, thus
being potentially at higher risk of treatment toxicity. Moreover,
about 95% of our patients had PSX2, while in the IDEAL-1 trial
only 12% of patients had PS 2 (Fukuoka et al, 2003). The reported
antitumour activity (3.4% of PR and 15.2% of overall disease
control) is to be considered modest, but achieved in heavily
pretreated patients with no further therapeutic options.
In our opinion, single-agent gefitinib is worthy of testing in the
near future for elderly and poor PS patients with advanced NSCLC
even as first-line treatment. The present retrospective analysis may
constitute an impulse for prospective clinical trials.
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